Commercial bioprocessing questions with Pratima Cherukuri, CSO

Scroll Down

In the Nov/Dec issue of European Pharmaceutical Manufacturer, Pratima Cherukuri, Chief Scientific Officer at Genezen answers vital questions surrounding bioprocessing at commercial scale and provides insight into the key challenges involved.

Read the full article here: European Pharmaceutical Manufacturer – Nov/Dec 2021

You may also be interested in...

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more

Genezen delivers next phase of cGMP…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more